Last updated:
October 18, 2008
 Documents
identified with this icon are in Portable Document Format (PDF) and
require the Adobe Acrobat Reader
6
Perinatal Data are integrated with Perinatal Conference Data in the Perinatal
Data Page.
Pediatric
Data are integrated with Pediatric Conference Data in the
Pediatric Data Page
ABC/3TC/ZDV data are indexed on the
Trizavir
Web
-
PDF POSTER
Abacavir Stimulates Hsp70 Redistribution in Antigen-presenting Cells of
Patients with
Hypersensitivity: Association with Type-I Alcohol Dehydrogenase Activity
A Martin, C Almeida, D Nolan. et al
PDF Poster
Abstract
-
PDF POSTER
Increased Rate and Severity of Abacavir-associated Hypersensitivity
Reaction in
Randomized
Controlled Clinical Trials
A James, R
Johann-Liang
PDF Poster
Abstract
-
PDF POSTER
Once-daily Administration of Abacavir Is not a Clinical Risk Factor for
Suspected
Hypersensitivity Reactions in Clinical Trials, and Rash Alone Is not
Sufficient to
Diagnose the Reaction
C Brothers, A Cutrell,
H Zhao, et al
PDF Poster
Abstract
-
PDF POSTER
Abacavir + Lamivudine Fixed Dose Combination Tablet Once Daily
Compared with
Abacavir and Lamivudine Twice Daily in HIV-1-infected Subjects
(ESS30008)
N Sosa , C Hill-Zabala
, E DeJesus, et al
PDF Poster
Abstract-
A Randomized Comparison between Abacavir and Stavudine, both
Combined with
Lamivudine/Efavirenz, in Antiretroviral-Naive Patients. Final
96-Week Results of the
ABCDE Study
D Podzamczer, E Ferrer, P Sanchez,
et al
Abstract
-
A 48-week, Randomized, Open-label Comparative Study of Tenofovir
DF vs Abacavir as
Substitutes for a Thymidine Analog in Persons with Lipoatrophy
and Sustained Virological
Suppression on HAART
G Moyle, C
Sabin, J Cartledge, et al
Abstract
|
-
Initial therapy with Abacavir/ Lamivudine
(ABC+3TC) combined with Efavirenz (NNRTI), Amprenavir/
Ritonavir (PI) or Stavudine (NRTI): ESS40001(CLASS)
JA Bartlett, J Johnson, G Herrera, et
al
Abstract
-
96 Week lipids and anthropometrics for subjects receiving initial therapy
with abacavir+lamivudine
(ABC+3TC) combined with efavirenz (NNRTI), amprenavir/ritonavir (PI) or
stavudine (NRTI):
ESS40001
(CLASS)
K Sathasivam, SK Griffith, J Bartlett, et al
Abstract
-
Analysis of the virologic response to abacavir-containing salvage HAART
regimens on the basis
of HIV-1 genotypic resistance to abacavir as interpreted by 15 distinct
rules
S Di Giambenedetto, CF Perno, A Cingolani, et al
Abstract
-
Abacavir and tenofovir combination therapy in clinical practice
DJ Ward
Abstract
-
Rapid oral desensitization to Abacavir in case of probable
hypersensitivity
A Ulmer, M Mueller, B Frietsch
Abstract
-
Lack of an intracellular drug interaction between Tenofovir DF and
Abacavir in patients receiving
triple nucleoside regimens
T Hawkins, W Veikley, R St Claire, et al
Abstract
-
Analysis of the effect of baseline resistance and clade on 48-week
efficacy of once-daily (OAD)
or twice-daily (BID) abacavir (ABC) in combination with OAD lamivudine
(3TC) and efavirenz
(EFV):a sub-analysis of ZODIAC
G Moyle, D Gordon, J Hernandez, T et al
Abstract
-
Long-term (>48 week) safety of abacavir (ABC) once daily (OAD) or twice
daily (BID), in
combination
with lamivudine (3TC) OAD OR BID and efavirenz (EFV) OAD
D Gordon, J Hernandez, A Cutrell, et al
Abstract
-
Abacavir (ABC) has a similar safety profile when administered once daily
(OAD) or twice daily
(BID) in
combination with lamivudine (3TC) and efavirenz (EFV) once daily to
antiretroviral therapy
(ART)-naïve,
HIV-infected adults
JE Hernandez, D Gordon, A Cutrell, et al
Abstract
-
Antiviral activity of Abacavir in combination with Tenofovir as backbone
of HAART in heavily
pretreated
patients
CK Schewe, A Adam, H Goey, et al
Abstract
-
Benefit in the lipid profile after substitution of abacavir
for stavudine
T García-Benayas, F
Blanco, A Alcolea, et al
Abstract
-
Evaluation of abacavir (ABC) plus tenofovir DF (TDF) in multiple drug
regimens (MDR)
M Harris, PR Harrigan, JS Montaner., et al
Abstract
|
-
PDF POSTER
Analysis of Virologic Failure in a Clinical Trial of
Abacavir Once Daily versus Twice Daily
with
Lamivudine and Efavirenz
C Craig, C Stone, T Bonny, et al.
PDF
Poster
Abstract
-
PDF POSTER
Treatment Emergent Mutations for Previously Naïve
HIV-infected Adults Failing
ZDV+3TC+EFZ
and ABC+3TC+EFV
D Irlbeck, E Rouse, S Castillo, et al.
PDF
Poster
Abstract
-
PDF POSTER
Carriage of HLA-B*5701 and a Haplotypic
Hsp70-Hom Variant Is Associated with a Class
I MHC-restricted
Hypersensitivity Response to Abacavir
AM Martin, CA Almeida, D Nolan. et al.
PDF
Poster
Abstract
-
PDF POSTER
Partial Improvement of Mitochondrial Dysfunction
48 weeks after Replacement of Stavudine
with
either Abacavir or Zidovudine
G McComsey, C Hoppel, V Williams, et al
PDF
Poster
Abstract-
Low Genetic Barrier to Resistance Is a Possible Cause of Early
Virologic Failures in
Once-Daily
Regimen of Abacavir, Lamivudine, and Tenofovir:
The Tonus Study
R
Landman, G Peytavin, D Descamps, et al
Abstract
-
Randomized, Placebo-Controlled Trial of Abacavir Intensification
in HIV-1-infected Adults with
Plasma
HIV RNA <500 Copies/mL
S Hammer, R Bassett, M Fischl, et al
Abstract
|
|
Conferences
Main Page
PDF Poster
